Klotho Neurosciences Shares Surge 37.94% Amid Key Updates
By ATTN Desk · Editorial oversight: Sean Han
Klotho Neurosciences Inc.
Introduction
Klotho Neurosciences Inc. (NASDAQ: KLTO) is a biopharmaceutical company focused on developing disease-modifying cell and gene therapies for neurodegenerative and age-related cognitive disorders. The company’s core platform centers on a patented form of the human α-Klotho gene (s-KL), which is delivered via adeno-associated virus (AAV) vectors to produce a therapeutic Klotho protein.
Corporate Structure
Employee Count
• As of June 12, 2025, Klotho Neurosciences reports 2–10 full-time employees.
Leadership Team
- Dr. Joseph Sinkule
• Founder, Chief Executive Officer & Chairman of the Board
• Over 40 years of experience in drug, biologic, and medical device research and development, as well as commercialization. - Mr. Jeffrey LeBlanc
• Chief Financial Officer
• Over 20 years of experience in financial operations, venture capital, and mergers and acquisitions. - Dr. Bradford A. Navia
• Chief Medical Advisor
• 18 years of experience in clinical development within neurology and psychiatry. - Dr. Miguel Chillón Rodríguez
• Chief Scientific Officer (Consultant)
• Inventor of the α-Klotho patents and expert in gene therapy vector technology. - Dr. Shalom Hirschman
• Medical Advisor & Director
• Former department chair at Mount Sinai School of Medicine.
Additional board members include Dr. Samuel Zentman and Mr. Jon McGarity, contributing finance, technology, and biotechnology commercialization experience.
Developments and News
- December 3, 2024
– Appointment of Riad El-Dada, former U.S. President of Merck, to the Board of Directors. - June 2, 2025
– Form 8-K filed (Items 5.07 & 9.01) reporting material corporate developments. - June 10, 2025
– Form 8-K filed (Items 1.01, 3.02, 7.01 & 9.01) disclosing significant events. - June 11, 2025
– Form 8-K filed (Items 1.01, 3.02 & 9.01).
– Shares closed at $2.0001, reflecting a change of 37.94% with a trading volume of 6,111,476 shares.
Financial and Strategic Analysis
Key Metrics (as of June 11, 2025)
| Metric | Value |
|---|---|
| Share price | $2.0001 |
| Daily change | +37.94% |
| Volume | 6,111,476 |
| 52-Week range | $0.1140 – $6.8300 |
| Market capitalization | $47.12 million |
| Net income (TTM) | –$7.71 million |
| Diluted EPS (TTM) | –$0.27 |
| Total cash (most recent quarter) | $0.57 million |
| Total debt/equity (most recent quarter) | 276.8% |
| Return on assets (TTM) | –151.41% |
| Return on equity (TTM) | –1,544.44% |
| Beta (5Y monthly) | 0.14 |
Strategic Initiatives
- Pipeline Focus
• The lead program targets amyotrophic lateral sclerosis (ALS), followed by future programs aimed at Alzheimer’s and Parkinson’s disease. - Technology Platform
• The company holds an exclusive license from Universitat Autònoma de Barcelona for the secreted α-Klotho (s-KL) gene.
• Continual improvements to AAV vector technology are aimed at enhancing safety, potency, and durability. - Collaborations & Intellectual Property
• Partnerships are established with academic institutions for vector design and preclinical research.
• The company has a strong portfolio of intellectual property covering s-KL sequences and associated delivery methods.
Market Position and Industry Context
- Biotech Segment: The company is involved in gene and cell therapies targeting neurodegenerative diseases.
- Competitive Landscape: The company faces limited direct competition in α-Klotho–based therapies while encountering broader competition from other gene therapy firms targeting ALS and Alzheimer’s.
- Volatility & Liquidity: The stock has shown significant price movement with a 37.94% increase on the reporting day and moderate trading volume compared to average daily volumes.
- Financial Profile: As an early-stage company, Klotho Neurosciences does not yet generate commercial revenue and relies on equity financing and partnerships to fund research and development initiatives.
tl;dr
• On June 11, 2025, KLTO shares increased by 37.94% to $2.0001 on a trading volume of 6.1 million.
• Between June 2 and June 11, 2025, the company filed three Form 8-K reports disclosing significant corporate events.
• The board expanded with the appointment of Riad El-Dada on December 3, 2024.
• Ongoing focus on advancing α-Klotho gene therapy programs for ALS, Alzheimer’s, and Parkinson’s disease.
• Future outlook is dependent on advancements in preclinical research, partnership agreements, and additional financing.